Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP1.13
- Development stage
- Preclinical
- Lead developer
- SASPiPhi
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
SP1.13 is a bacteriophage-based therapeutic candidate being developed by SASPiPhi for the treatment of endocarditis caused by Staphylococcus aureus. It utilizes the proprietary SASPject platform, which employs engineered bacteriophages to deliver Small Acid-Soluble Spore Proteins (SASPs) to target bacterial cells. Once inside the pathogen, the SASPs bind to the bacterial DNA in a sequence-independent manner, effectively silencing the genome and preventing replication and transcription. This mechanism of action is designed to be effective against both antibiotic-sensitive and antibiotic-resistant strains, such as MRSA. SP1.13 is currently in the preclinical stage of development.
- Other names
- SP1.13-SASPiPhiSP-1.13-SASPiPhiSP 1.13-SASPiPhiSASPiPhi-Staphylococcus aureus-bacteriophage-based therapy
02
Targets
ClfA (Clumping factor A)
Beyond the preview
Go deeper on SP1.13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP1.13.